Umoja wa Ulaya - Kifaransa - EMA (European Medicines Agency)

janssen-cilag international nv - rilpivirine - infections au vih - antiviraux à usage systémique - rekambys is indicated, in combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (hiv 1) infection in adults who are virologically suppressed (hiv-1 rna < 50 copies/ml) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the nnrti and ini class.

Umoja wa Ulaya - Kifaransa - EMA (European Medicines Agency)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vaccins - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. l'utilisation de ce vaccin doit être en conformité avec les recommandations officielles.

Umoja wa Ulaya - Kifaransa - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - carcinome, poumon non à petites cellules - agents antinéoplasiques - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Umoja wa Ulaya - Kifaransa - EMA (European Medicines Agency)

amgen europe bv - sotorasib - carcinome, poumon non à petites cellules - agents antinéoplasiques - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.

Umoja wa Ulaya - Kifaransa - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - le myélome multiple - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Umoja wa Ulaya - Kifaransa - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - le myélome multiple - agents antinéoplasiques - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Umoja wa Ulaya - Kifaransa - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - sugammadex sodium - blocus neuromusculaire - tous les autres produits thérapeutiques - inversion du blocage neuromusculaire induite par le rocuronium ou le vécuronium. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Umoja wa Ulaya - Kifaransa - EMA (European Medicines Agency)

janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - bénigne de la prostate tumeurs, résistant À la castration - agents antinéoplasiques - treatment of adult patients with prostate cancer.

Umoja wa Ulaya - Kifaransa - EMA (European Medicines Agency)

amgen technology (ireland) uc - eculizumab - hémoglobinurie paroxystique - immunosuppresseurs - bekemv is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). la preuve de l'avantage clinique est démontré chez les patients avec une hémolyse avec symptôme clinique(s) à titre indicatif de haute activité de la maladie, indépendamment de la transfusion de l'histoire (voir la section 5.

Umoja wa Ulaya - Kifaransa - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - le myélome multiple - agents antinéoplasiques - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.